Cargando…

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study

AIM: To evaluate the effect of canagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria. METHODS: The CANPIONE study is a multicentre, randomized, parall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyamoto, Satoshi, Heerspink, Hiddo J. L., de Zeeuw, Dick, Toyoda, Masao, Suzuki, Daisuke, Hatanaka, Takashi, Nakamura, Tohru, Kamei, Shinji, Murao, Satoshi, Hida, Kazuyuki, Ando, Shinichiro, Akai, Hiroaki, Takahashi, Yasushi, Koya, Daisuke, Kitada, Munehiro, Sugano, Hisashi, Nunoue, Tomokazu, Nakamura, Akihiko, Sasaki, Motofumi, Nakatou, Tatsuaki, Fujimoto, Kei, Kawanami, Daiji, Wada, Takashi, Miyatake, Nobuyuki, Yoshida, Michihiro, Shikata, Kenichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Clinical Study Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545385/ https://www.ncbi.nlm.nih.gov/pubmed/35491532 http://dx.doi.org/10.1111/dom.14731

Ejemplares similares

Combination therapy with an angiotensin‐converting‐enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy
por: Nakamura, Akihiko, et al.
Publicado: (2012)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies
por: Olde Engberink, Rik H. G., et al.
Publicado: (2016)

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
por: Kodera, Ryo, et al.
Publicado: (2017)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

SIRT1 in Type 2 Diabetes: Mechanisms and Therapeutic Potential
por: Kitada, Munehiro, et al.
Publicado: (2013)

Renal Protective Effects of Resveratrol
por: Kitada, Munehiro, et al.
Publicado: (2013)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Kawanami, Daiji, et al.
Publicado: (2020)

The Role of Bone-Derived Hormones in Glucose Metabolism, Diabetic Kidney Disease, and Cardiovascular Disorders
por: Takashi, Yuichi, et al.
Publicado: (2022)

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2019)

Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
por: Osonoi, Takeshi, et al.
Publicado: (2018)

Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
por: Maruyama, Takashi, et al.
Publicado: (2019)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Randomized trial of an intensified, multifactorial intervention in patients with advanced‐stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan)
por: Shikata, Kenichi, et al.
Publicado: (2020)

Rodent models of diabetic nephropathy: their utility and limitations
por: Kitada, Munehiro, et al.
Publicado: (2016)

The protective role of Sirt1 in vascular tissue: its relationship to vascular aging and atherosclerosis
por: Kitada, Munehiro, et al.
Publicado: (2016)

Sirtuins and Renal Oxidative Stress
por: Ogura, Yoshio, et al.
Publicado: (2021)

NAD(+) Homeostasis in Diabetic Kidney Disease
por: Xu, Jing, et al.
Publicado: (2021)

Significance of Metformin Use in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2020)

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

Autophagy as a Therapeutic Target in Diabetic Nephropathy
por: Tanaka, Yuki, et al.
Publicado: (2012)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

The Role of CD38 in the Pathogenesis of Cardiorenal Metabolic Disease and Aging, an Approach from Basic Research
por: Kitada, Munehiro, et al.
Publicado: (2023)

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program
por: Young, Tamara K., et al.
Publicado: (2021)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
por: Li, Jing‐Wei, et al.
Publicado: (2022)

Gastric Mucosal Changes Caused by Lugol's Iodine Solution Spray: Endoscopic Features of 64 Cases on Screening Esophagogastroduodenoscopy
por: Tsurumaru, Daisuke, et al.
Publicado: (2010)

Resveratrol Improves Oxidative Stress and Protects Against Diabetic Nephropathy Through Normalization of Mn-SOD Dysfunction in AMPK/SIRT1-Independent Pathway
por: Kitada, Munehiro, et al.
Publicado: (2011)

Diabetic angiopathy and angiogenic defects
por: Xu, Ling, et al.
Publicado: (2012)

A Low-Protein Diet for Diabetic Kidney Disease: Its Effect and Molecular Mechanism, an Approach from Animal Studies
por: Kitada, Munehiro, et al.
Publicado: (2018)

The impact of dietary protein intake on longevity and metabolic health
por: Kitada, Munehiro, et al.
Publicado: (2019)

Sirtuins and Type 2 Diabetes: Role in Inflammation, Oxidative Stress, and Mitochondrial Function
por: Kitada, Munehiro, et al.
Publicado: (2019)

Supplementation with Red Wine Extract Increases Insulin Sensitivity and Peripheral Blood Mononuclear Sirt1 Expression in Nondiabetic Humans
por: Kitada, Munehiro, et al.
Publicado: (2020)

Relationship Between Autophagy and Metabolic Syndrome Characteristics in the Pathogenesis of Atherosclerosis
por: Xu, Jing, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
por: Xu, Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mi8mcp7jhm43sogl6filuas3vg